Print

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri

Clinicaltrials.gov identifier:
NCT03462342 (https://clinicaltrials.gov/show/NCT03462342)


Recurrent ovarian cancer

About the Study

This study is no longer recruiting patients. 

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

 

This Study is Open To:

This study is no longer recruiting patients. 

This Study is Not Open To:

This study is no longer recruiting patients. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.